Placental cellular immune response in women infected with human parvovirus B19 during pregnancy

Clinical and Diagnostic Laboratory Immunology

Volumn 8, Issue 2, 2001, Pages 288-292

  Jordan, J A ^a   Huff, D ^a   DeLoia, J A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CYTOKINE; INTERLEUKIN 2;

ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONGENITAL INFECTION; CONTROLLED STUDY; ERYTHEMA INFECTIOSUM; FEMALE; FETUS HYDROPS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PARVOVIRUS; PLACENTA; PREGNANCY; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD3; DISEASE TRANSMISSION, VERTICAL; FEMALE; HUMANS; HYDROPS FETALIS; INTERLEUKIN-2; LYMPHOCYTE COUNT; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; T-LYMPHOCYTES; VIRAL VACCINES;

EID: 0035106935     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.8.2.288-292.2001     Document Type: Article

References (37)

1. Experimental parvoviral infection in humans
2. The interleukin 2 gene is expressed in the syncytiotrophoblast of the human placenta
3. Erythrocyte P antigen: Cellular receptor for B19 parvovirus
4. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen)
5. Cytokines determining the success or failure of pregnancy
6. Detection of parvovirus B19 DNA, antigen, and particles in the human fetus
7. Feto-placentary pathology in human parvovirus B19 infection
8. Parvovirus B19 infection and its significance in pregnancy
9. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome
10. Detection of human parvovirus B19-specific IgM and IgG antibodies using a recombinant viral VP1 antigen expressed in insect cells and estimation of time of infection by testing for antibody avidity
11. Pathogenic implication of Interleukin-2 expressed in preeclamptic decidual tissues: A possible mechanism of deranged vasculature of the placenta associated with preeclampsia
12. Transcriptional regulation of the 1L-2 gene
13. An epidemic of parvovirus B19 in a population of 3.596 pregnant women: A study of sociodemographic and medical risk factors
14. Cytokine production and cytokine receptor expression by cells of the human first trimester placentaluterine interface
15. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis
16. Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia coli-based VP1 EIA for detection of human parvovirus B19 immunoglobulin M and immunoglobulin G in sera of pregnant women
17. Globoside expression within the human placenta
18. The placenta and viral infections
19. Screening for cytokine mRNA in human villous and extravillous trophoblasts using the reverse-transcriptase polymerase chain reaction (RT-PCR)
20. Risk of adverse outcomes of pregnancy after human parvovirus B19 infection
21. Serologic and virologic evidence for frequent intrauterine transmission of human parvovirus B19 with a primary maternal infection during pregnancy
22. The immune response to B19 parvovirus-like virus inhibits haematopoietic colony formation in vitro
23. Immediate and long term outcome of human parvovirus B19 infection in pregnancy
24. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythorid lineage cells
25. Correlation between cytokine levels of amniotic fluid and histological chorioamnionitis in preterm delivery
26. Parvovirus as a cause of hydrops fetalis: Detection by in situ DNA hybridisation
27. Prospective study of human parvovirus (B19) infection in pregnancy
28. The role of cytokines in gestation
29. Management and outcomes of pregnancies complicated by human B19 parvovirus infection: A prospective study
30. Murine experimental abortion by 1L-2 administration is caused by activation of cytotoxic T lymphocytes and placental apoptosis
31. Parvovirus B19 infection: Association with third-trimester intrauterine fetal death
32. Accurate serodiagnosis of B19 parvovirus infections by measurement of IgG avidity
33. Risk factors for parvovirus B19 infection in pregnancy
34. Lymphoproliferative responses after infection with human parvovirus B19
35. Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection
36. Parvovirus B19 associated with fetal abnormality
37. The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection: Report of 10 cases and meta-analysis